AbbVie Completes Acquisition of Landos Biopharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Deutsche Bank Reiterates Hold Rating on Abbvie (ABBV)
May 24, 2024 8:31 AM EDTDeutsche Bank analyst James Shin reiterated a Hold rating and $175.00 price target on Abbvie (NYSE: ABBV).
The analyst comments "IMS/IQVIA data for the week ending 5/17/24 show branded Humira with 72.2% share (+0.4% w/w) of Adalimumab scripts. Co-branded Humira (Cordavis x ABBV) captured 9.7% share (+0.2% w/w) of Adalimumab scripts. On a combined basis (branded +... More
